Century Therapeutics (IPSC) Return on Capital Employed (2021 - 2026)
Century Therapeutics (IPSC) posted quarterly Return on Capital Employed of 44.01% for Q1 2026, down 3381.0% year-over-year from 1.34% in Q1 2025, and down 445.57% quarter-over-quarter from 8.07% in Q4 2025.
Century Therapeutics (IPSC) Return on Capital Employed (2021 - 2026) Analysis & Trends
Century Therapeutics (IPSC) has reported Return on Capital Employed for 6 consecutive years, with 44.01% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed fell 3381.0% year-over-year to 44.01%; the TTM figure through Mar 2026 stood at 44.01% (down 3381.0% YoY), while the FY2025 annual figure was 6.44%, up 5437.0% from the prior year.
- Return on Capital Employed eased to 44.01% in Q1 2026 per IPSC's latest filing, from 8.07% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 8.07% in Q4 2025 and bottomed at 57.29% in Q4 2024.
- Historically, Return on Capital Employed has averaged 29.67% across 5 years, with a median of 28.96% in 2023.
- Annual changes were most pronounced in 2025 — Return on Capital Employed surged 4922 bps — and 2026, when it slumped 3381 bps.
- Century Therapeutics' Return on Capital Employed stood at 28.52% in 2022, then slumped by 42 bps to 40.56% in 2023, then sank by 41 bps to 57.29% in 2024, then soared by 86 bps to 8.07% in 2025, then slumped by 446 bps to 44.01% in 2026.
- Business Quant data shows IPSC's Return on Capital Employed at 44.01% in Q1 2026, 8.07% in Q4 2025, and 13.97% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Century Therapeutics | 346.65 Mn | 86.58 Mn | - | -40.10% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -40.10% |
| Mar 31, 2026 | -44.01% |
| Dec 31, 2025 | -8.07% |
| Sep 30, 2025 | -13.97% |
| Jun 30, 2025 | -11.42% |
| Mar 31, 2025 | -10.21% |
| Dec 31, 2024 | -57.29% |
| Sep 30, 2024 | -37.79% |
| Jun 30, 2024 | -40.03% |
| Mar 31, 2024 | -43.06% |
| Dec 31, 2023 | -40.56% |
| Sep 30, 2023 | -35.17% |
| Jun 30, 2023 | -31.66% |
| Mar 31, 2023 | -28.96% |
| Dec 31, 2022 | -28.52% |
| Sep 30, 2022 | -25.95% |
| Jun 30, 2022 | -23.58% |
| Mar 31, 2022 | -24.21% |
| Dec 31, 2021 | -21.67% |
| Sep 30, 2021 | -17.75% |